Art

J-GLOBAL ID：202002282723698508   Reference number：20A0513425

Successful Transition from Intravenous Epoprostenol to Oral Selexipag due to Effective Management of Side Effects in a Young Woman with Severe Idiopathic Pulmonary Arterial Hypertension

静注エポプロステノールから内服セレキシパグへの切り替えに,効果的な副作用対策により成功した若年女性の重症特発性肺動脈性肺高血圧症の1例

Author (5)： MURATSU NAOKO (国立循環器病研究セ 薬剤部) ,  FUKUI SHIGEFUMI (国立循環器病研究セ 心臓血管内科部門) ,  TERAKAWA NOBUE (国立循環器病研究セ 薬剤部) ,  OITA AKIRA (国立循環器病研究セ 薬剤部) ,  OGO TAKESHI (国立循環器病研究セ 心臓血管内科部門)
Material： 医療薬学  (Japanese Journal of Pharmaceutical Health Care and Sciences)
Volume： 46  Issue： 2  Page： 77-83  Publication year： Feb. 10, 2020 
JST Material Number： Y0888A  ISSN： 1346-342X  CODEN： IYRAA3  Document type： Article
Article type： 短報  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： Triple therapy ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0513425&from=J-GLOBAL&jstjournalNo=Y0888A") }}

JST classification (2)： Clinical application of vasoactive drugs and hypotensive drugs  (GW07050U) ,  Drug therapy(=pharmacotherapy)for cardiovascular system diseases  (GJ05020M)

Substance index (4)： Epoprostenol ,  Selexipag ,  Tadalafil ,  Macitentan

Reference (6)：

• 1)Humbert M, Sitbon O, Simonneau G, Treatment of pulmonary arterial hypertension, N Engl J Med, 2004, 351, 1425-1436.
• 2)Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension, N Engl J Med, 1996, 334, 296-301.
• 3)Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, Griphon Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension, N Engl J Med, 2015, 373, 2522-2533.
• 4)Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur Heart J, 2016, 37, 67-119.
• 5)Furukawa A, Tamura Y, Iwahori H, Goto M, Ohashi N, Okabe T, Kawamura A. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension, BMC Pulm Med, 2017, 17, 135.

Terms in the title (11)： 静注 ,  エポプロステノール ,  内服 ,  セレキシパグ ,  切り替え ,  副作用 ,  対策 ,  成功 ,  若年女性 ,  重症 ,  特発性肺動脈性肺高血圧症